Entero Therapeutics (FRA:366) Interest Expense : €-0.07 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entero Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Entero Therapeutics's interest expense for the three months ended in Mar. 2024 was € -0.06 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.07 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Entero Therapeutics's Operating Income for the three months ended in Mar. 2024 was € -8.49 Mil. Entero Therapeutics's Interest Expense for the three months ended in Mar. 2024 was € -0.06 Mil. Entero Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Entero Therapeutics Interest Expense Historical Data

The historical data trend for Entero Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entero Therapeutics Interest Expense Chart

Entero Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.39

-4.80

-0.01

-0.02

Entero Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.01	-	-0.01	-0.06

Entero Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.07 Mil.

Entero Therapeutics (FRA:366) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Entero Therapeutics's Interest Expense for the three months ended in Mar. 2024 was €-0.06 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-8.49 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €6.00 Mil.

Entero Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Entero Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Entero Therapeutics (FRA:366) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (FRA:366) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ENTO:USA

Address

777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431

Website

https://www.firstwavebio.com

First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Entero Therapeutics (FRA:366) Headlines

No Headlines